Press Releases

04.09.2015

Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research

04.07.2015

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

04.06.2015

Kathrin U. Jansen, Ph.D., to Lead Pfizer’s Vaccine Research and Development Unit

03.30.2015

Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

03.26.2015

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.23.2015

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

03.20.2015

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

03.18.2015

Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

03.12.2015

Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia

03.03.2015

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

02.26.2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

02.24.2015

Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diphtheria And Pertussis (Tdap) Vaccines In Adolescents